Baxa (Englewood, Colorado) reported the launch of its new microsite featuring the company's Skills Training, Academics and Resources (STAR) Center in Englewood. The specialty site focuses on providing complete user information for the expanding course offerings at the facility.

Currently, the STAR Center offers three courses in its clean room training facility. Baxa expects to continue adding to the curricula in 2009.

The new site offers online registration, an interactive tour of the training facilities and allows Baxa to relay the most up-to-date information regarding course schedules, content and technical support materials related to course content.

The STAR Center was launched in the fall of 2006. Program attendance is accepted on a first come, first served basis.

Baxa makes products that promote the safe and efficient preparation, handling, packaging and administration of medications.

Angel MedFlight launches 'One Touch Promise'

Angel MedFlight Worldwide Air Ambulance (Scottsdale, Arizona) is implementing services to align safe air medical transportation with overall cost savings to hospitals, insurance companies, and private payers with the "One Touch Promise."

Angel MedFlight's "One Touch Promise" was created to combat substandard service and to assist those in need of safe air medical transportation without sacrificing quality while providing affordable healthcare services. Angel MedFlight maintains a fleet of strategically positioned and dedicated air ambulance aircraft throughout the U.S. that it said provides the company with greater autonomy than any other air ambulance provider, as flights remaining vacant are minimized considerably, and as a result, cost savings are then passed on to the client.

Angel MedFlight is a provider of medical ground and air transport.

ED could be treated by gene therapy

Gene therapy may be a way to treat erectile dysfunction in men who do not respond to pills such as Viagra, researchers report.

Maxi-K gene therapy is a gene transfer that improves erectile dysfunction. Two studies using the gene were presented recently at the American Urological Association's annual meeting.

"Gene transfer technology has the potential for long-term improvement for erectile function," said lead researcher Arnold Melman, a professor of medicine at Albert Einstein College of Medicine (New York).

Melman noted that a recent survey showed that 50% of urologists would consider switching their patients from their current medications to gene transfer treatment. "So, we think this will be well-accepted by physicians and patients," he said.

Results of a phase I trial testing gene transfer in 11 men with erectile dysfunction who had failed other therapy showed that gene transfer was safe and also had restorative effects. Four different doses were tried during the trial. Men receiving the highest dose showed improvement for up to six months, Melman said.

"These men had normal sexual function for six months and then went back to the way they were," Melman said. He added that two doses a year would be enough for most men to maintain their normal sexual function.

Isotopes to play expanded role in modern medicines

Nuclear medicine, which uses medical isotopes to diagnose and treat many life-threatening diseases such as heart disease and cancer, is one of the fastest-growing segments in the health industry today. In the U.S. more than 12 million nuclear medicine procedures are performed annually. According to Citizens for Medical Isotopes, the demand for medical isotopes is projected to grow in the range of 8% to 20% per year for the next 20 years.

"Medical isotopes will play a major role in the advancement of 21st Century medicine," said Jim Katzaroff, chairman/president of Advanced Medical Isotope (Kennewick, Washington). Despite their widespread use, however, up to 90% of the medical isotopes used in American hospitals and clinics are imported and some of the most important medical isotopes remain in tragically short supply. As a result, life-saving medical research has been curtailed, hospitals across the country frequently postpone or cancel vital procedures, and patients suffer the consequences.

Advanced Medical Isotope recently received its radioactive material license with radioactive air emissions attachment, awarded by the state of Washington, which enables the company to produce, possess, or distribute radioisotopes. "This license allows us to proceed with startup operations of our nation's first compact proton linear accelerator used for medical isotope production," said Katzaroff. "Our goal is to ensure there are no obstacles in the way of getting patients the procedures they need."